Sci Rep manuscript!

22/04/2019

In collaboration with the Villagra lab (The George Washington University, DC, USA) and StarWise Therapeutics, LLC, we  demonstrated that selective HDAC6 inhibitors can be used as immunological priming agents to sensitize immunologically “cold” tumors and subsequently improve ongoing immune check-point blockade therapies.

News